Brief Summary
This study aims to determine whether patients with a high level of Amphiregulin/epiregulin (AREG/EREG) cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs cell markers for advancedat a late stage, far along stage colorectalrelating to the colon or rectum in the large bowel/intestine cancer have a better treatment response to a combined chemo- and biological regime.
Intervention/Treatment
- Drug: Cetuximab.
- Drug: Irinotecan.
- Drug: Fluorouracil.
Inclusion Criteria
- Patients aged greater than 18 years of age.
- ECOG performance status 0-1.
- Patients with advanced colorectal cancer.
- Primary tumoura tissue mass that forms from groups of unhealthy cells arising from right side of colonthe longest portion of the large bowel that absorbs water and salts from ingested food (proximal to the splenic flexure).
- RAS/BRAF wild type.
- Tumours with high AREG/EREG expression as determined by central laboratory testing.
- At least one measurable lesion as per RECIST 1.1 criteria.
- Receipt of fluoropyrimidine and oxaliplatin containing therapy (FOLFOX,CAPOX or FOLFOXIRI) +/- bevacizumab as part of the initial treatment of advanced disease, or progression within 6 months of completing oxaliplatin based adjuvant therapy for early stage disease.
- Fit for treatment with cetuximab and irinotecan based treatment.
- Life expectancy greater than 3 months.